Live price temporarily unavailable.
Surrozen (SRZN) is a Health Care company in the Russell 2000. Latest news and coverage below.
| FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | — | $0 | $12.5M | $0 | $10.7M | $3.48M |
| Growth (year over year) | — | — | — | −100.0% | — | −67.4% |
| Operating income | −$32.8M | −$54.4M | −$44.3M | −$45.8M | −$25.5M | −$42.1M |
| Operating margin | — | — | −354.7% | — | −239.7% | −1210.6% |
| Net income | −$32.7M | −$54.6M | −$36.0M | −$43.0M | −$63.6M | −$242.0M |
| Net margin | — | — | −288.0% | — | −596.6% | −6960.8% |
| EPS (diluted) | — | −$33.15 | −$15.56 | −$21.33 | −$21.67 | −$32.37 |
| Balance sheet | ||||||
| Cash and equivalents | $35.0M | $33.1M | $24.7M | $36.0M | $34.6M | $89.2M |
| Total assets | $62.1M | $137.2M | $89.4M | $46.1M | $48.5M | $98.7M |
| Total liabilities | $14.8M | $27.5M | $13.4M | $8.14M | $69.8M | $286.5M |
| Shareholders' equity | $47.3M | $109.7M | $76.0M | $37.9M | −$21.4M | −$187.8M |
| Cash flow | ||||||
| Operating cash flow | −$29.1M | −$48.8M | −$44.1M | −$40.4M | −$17.6M | −$30.2M |
| Capital expenditure | $874.0K | $1.27M | $728.0K | $398.0K | $26.0K | $128.0K |
| Free cash flow | −$30.0M | −$50.1M | −$44.9M | −$40.8M | −$17.7M | −$30.4M |
| Share buybacks | — | $0 | $2.61M | $0 | — | — |
| Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $10.0M | — | $983.0K | $983.0K | $983.0K | $528.0K | $5.00M | $5.00M |
| Growth (year over year) | — | — | — | — | −90.2% | — | +408.6% | +408.6% |
| Operating income | $1.23M | — | −$9.55M | −$9.02M | −$10.9M | −$12.6M | −$10.5M | −$10.4M |
| Operating margin | 12.3% | — | −971.6% | −917.3% | −1107.3% | −2393.8% | −209.1% | −207.4% |
| Net income | −$1.43M | — | −$27.0M | $39.7M | −$71.6M | −$183.2M | −$127.5M | $50.2M |
| Net margin | −14.3% | — | −2743.6% | 4043.3% | −7288.2% | −34689.2% | −2550.1% | 1003.5% |
| EPS (diluted) | −$0.44 | — | −$7.43 | $2.55 | −$8.36 | −$19.13 | −$11.65 | −$0.41 |
| Balance sheet | ||||||||
| Cash and equivalents | $31.0M | $34.6M | $101.6M | $90.4M | $81.3M | $89.2M | $106.9M | $102.0M |
| Total assets | $48.0M | $48.5M | $114.8M | $102.7M | $94.0M | $98.7M | $120.7M | $115.6M |
| Total liabilities | $42.3M | $69.8M | $109.2M | $55.6M | $117.6M | $286.5M | $398.9M | $334.3M |
| Shareholders' equity | $5.67M | −$21.4M | $5.67M | $47.1M | −$23.5M | −$187.8M | −$278.1M | −$218.7M |
| Cash flow | ||||||||
| Operating cash flow | −$6.75M | — | −$9.28M | −$6.11M | −$9.04M | −$5.81M | −$12.5M | −$7.42M |
| Capital expenditure | $0 | — | $27.0K | $18.0K | $24.0K | $59.0K | $120.0K | $19.0K |
| Free cash flow | −$6.75M | — | −$9.31M | −$6.13M | −$9.06M | −$5.87M | −$12.6M | −$7.43M |
From Surrozen's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning Surrozen in our feed yet.